Astraveus Highlights Early Efficiency Data for Lakhesys Cell Therapy Platform

According to a recent LinkedIn post from Astraveus, the company recently hosted representatives from Institut Paoli-Calmettes for evaluation runs of its Lakhesys microfluidic platform. The post describes head‑to‑head comparisons with an unnamed industry benchmark, indicating roughly 2.5x higher transduction efficiency for Lakhesys without additional reagents.

The LinkedIn post suggests these are early results from a new functional prototype and highlights positive qualitative feedback from experienced cell therapy manufacturing leaders. By emphasizing microfluidic processing and low‑volume lentiviral delivery, the content points to potential reductions in reagent usage, which could translate into lower manufacturing costs for CAR‑T and other cell therapies.

As shared in the post, Institut Paoli-Calmettes experts characterized Lakhesys as a meaningful innovation that may challenge existing practices around reagent volumes. If further validation confirms higher transduction rates with fewer inputs, Astraveus could strengthen its value proposition in decentralized, point‑of‑care cell therapy manufacturing.

For investors, the post may be interpreted as an early signal of technical differentiation rather than definitive clinical or commercial validation. Continued evaluation programs with external partners, as referenced in the post, could help de‑risk the technology, support future partnering opportunities, and potentially enhance Astraveus’s position within the cell therapy manufacturing tools segment.